EP0749313A4 - Methode de traitement d'etats associes au recepteur 5ht 2b - Google Patents

Methode de traitement d'etats associes au recepteur 5ht 2b

Info

Publication number
EP0749313A4
EP0749313A4 EP95914014A EP95914014A EP0749313A4 EP 0749313 A4 EP0749313 A4 EP 0749313A4 EP 95914014 A EP95914014 A EP 95914014A EP 95914014 A EP95914014 A EP 95914014A EP 0749313 A4 EP0749313 A4 EP 0749313A4
Authority
EP
European Patent Office
Prior art keywords
treating
related conditions
receptor related
receptor
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95914014A
Other languages
German (de)
English (en)
Other versions
EP0749313A1 (fr
Inventor
James Edmund Audia
Marlene Lois Cohen
Jaswant Singh Gidda
David Lloyd Garver Nelson
Stephen Richard Baker
Jesus Ezquerra-Carrera
Carlos Lamas-Peteira
Concepcion Pedregal-Tercero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/380,566 external-priority patent/US5688807A/en
Priority claimed from US08/380,565 external-priority patent/US5663178A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0749313A1 publication Critical patent/EP0749313A1/fr
Publication of EP0749313A4 publication Critical patent/EP0749313A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
  • Liquid Crystal Substances (AREA)
EP95914014A 1994-03-11 1995-03-10 Methode de traitement d'etats associes au recepteur 5ht 2b Withdrawn EP0749313A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US380566 1989-07-14
US380565 1989-07-14
US21262294A 1994-03-11 1994-03-11
US212622 1994-03-11
US08/380,566 US5688807A (en) 1994-03-11 1995-02-06 Method for treating 5HT2B receptor related conditions
US08/380,565 US5663178A (en) 1995-02-06 1995-02-06 Tetrahydro-beta carbolines
PCT/US1995/003099 WO1995024200A1 (fr) 1994-03-11 1995-03-10 Methode de traitement d'etats associes au recepteur 5ht¿2b?

Publications (2)

Publication Number Publication Date
EP0749313A1 EP0749313A1 (fr) 1996-12-27
EP0749313A4 true EP0749313A4 (fr) 2001-10-24

Family

ID=27395770

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95914014A Withdrawn EP0749313A4 (fr) 1994-03-11 1995-03-10 Methode de traitement d'etats associes au recepteur 5ht 2b

Country Status (11)

Country Link
EP (1) EP0749313A4 (fr)
JP (1) JPH09510216A (fr)
CN (1) CN1148340A (fr)
AU (1) AU679635B2 (fr)
CA (1) CA2185236A1 (fr)
CZ (1) CZ264996A3 (fr)
FI (1) FI963571A (fr)
HU (1) HUT75522A (fr)
IL (1) IL112958A0 (fr)
NO (1) NO963785L (fr)
WO (1) WO1995024200A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CA2218143A1 (fr) * 1995-04-18 1996-10-24 Eli Lilly And Company Procede d'utilisation de composes d'ergoline pour effectuer des fonctions physiologiques et pathologiques sur le recepteur 5-ht7
GB9523999D0 (en) 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
JP2000507269A (ja) * 1996-03-15 2000-06-13 イーライ・リリー・アンド・カンパニー 一般かぜまたはアレルギー性鼻炎の処置方法
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
US5886003A (en) * 1996-03-25 1999-03-23 Eli Lilly And Company Methods of treating or ameliorating the symptoms of venomous bites and stings
IL126063A (en) * 1996-03-25 2002-04-21 Lilly Co Eli Medicinal products containing ulanzapine for the treatment of migraine pain
BR9708347A (pt) * 1996-03-25 1999-08-03 Lilly Co Eli Compostos de tetrahidorbeta-carbonila
WO2000069437A1 (fr) 1999-05-18 2000-11-23 Synaptic Pharmaceutical Corporation Utilisation d'agonistes ou d'antagonistes vis-a-vis du recepteur 5-ht7 pour traiter les troubles de la vessie
DK1188747T3 (da) 1999-05-24 2006-01-23 Mitsubishi Pharma Corp Phenoxypropylaminforbindelser
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
EP1626715B1 (fr) * 2003-05-09 2008-09-10 Laboratorios Del Dr. Esteve, S.A. Utilisation de derives sulfamides pour la fabrication d'un medicament pour la prophylaxie et/ou le traitement de troubles d'ingestion des aliments
WO2006085510A1 (fr) * 2005-02-08 2006-08-17 Astellas Pharma Inc. Remede pour le syndrome du colon irritable (sci)
CA2617473A1 (fr) 2005-08-08 2007-02-15 Astellas Pharma Inc. Derive d'acylguanidine ou sel de celui-ci
ATE542794T1 (de) 2006-02-20 2012-02-15 Astellas Pharma Inc Pyrrolderivat oder salz davon
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
WO2010058858A1 (fr) 2008-11-21 2010-05-27 ラクオリア創薬株式会社 Nouveau dérivé de pyrazole-3-carboxamide doté d’une activité antagoniste du récepteur 5-ht2b
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2011038162A1 (fr) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles et leurs méthodes d'utilisation
CN102724875B (zh) * 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
WO2017172957A1 (fr) 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Modulateurs du récepteur des œstrogènes
CA3130767A1 (fr) * 2019-02-27 2020-09-03 The Regents Of The University Of California Indoles n-substitues et autres heterocycles destines au traitement des troubles du cerveau
US11278532B2 (en) 2019-08-06 2022-03-22 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
CN116514824A (zh) * 2022-01-29 2023-08-01 上海科技大学 三并环类化合物、其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
US4731358A (en) * 1982-10-29 1988-03-15 Schering Aktiengesellschaft β-carbolines and their use as tranquilizers
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
EP0620222A2 (fr) * 1993-04-14 1994-10-19 Eli Lilly And Company Tétrahydro-bêta-carbolines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520024A (en) * 1983-02-11 1985-05-28 Eli Lilly And Company Method of selectively blocking peripheral vascular serotonergic receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
US4731358A (en) * 1982-10-29 1988-03-15 Schering Aktiengesellschaft β-carbolines and their use as tranquilizers
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
EP0620222A2 (fr) * 1993-04-14 1994-10-19 Eli Lilly And Company Tétrahydro-bêta-carbolines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AUDIA, J. E. ET AL.: "Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B contractile receptor in the rat stomach fundus", J. MED. CHEM., vol. 39, 1996, pages 2773 - 2780, XP002167539 *
GLENNON, R. A.: "Central Serotonin Receptors as Targets for Drug Research", J. MED. CHEM., vol. 30, 1987, pages 1 - 12, XP002167538 *
MARTIN G R ET AL: "RECEPTORS FOR 5-HYDROXYTRYPTAMINE: CURRENT PERSPECTIVES ON CLASSIFICATION AND NOMENCLATURE", NEUROPHARMACOLOGY,GB,PERGAMON PRESS, OXFORD, vol. 33, no. 3/04, 1 March 1994 (1994-03-01), pages 261 - 273, XP002037183, ISSN: 0028-3908 *
ONDA, M.; KAWANISHI, M.: "Analogs of Rauwolfia Alkaloids", J. PHARM. SOC. JPN., vol. 76, 1956, pages 966 - 968, XP000985848 *
See also references of WO9524200A1 *
SPÄTH, E. ET AL: "SYNTHESEN VON 4-CARBOLINEN", CHEMISCHE BERICHTE,XX,XX, vol. 120, 18 July 1930 (1930-07-18), pages 2102 - 2111, XP000917524, ISSN: 0009-2940 *

Also Published As

Publication number Publication date
HUT75522A (en) 1997-05-28
IL112958A0 (en) 1995-06-29
FI963571A0 (fi) 1996-09-10
HU9602482D0 (en) 1996-11-28
WO1995024200A1 (fr) 1995-09-14
CN1148340A (zh) 1997-04-23
NO963785L (no) 1996-11-01
JPH09510216A (ja) 1997-10-14
NO963785D0 (no) 1996-09-10
AU2118695A (en) 1995-09-25
AU679635B2 (en) 1997-07-03
FI963571A (fi) 1996-11-08
CA2185236A1 (fr) 1995-09-14
EP0749313A1 (fr) 1996-12-27
CZ264996A3 (cs) 1998-01-14

Similar Documents

Publication Publication Date Title
EP0749313A4 (fr) Methode de traitement d'etats associes au recepteur 5ht 2b
IL126203A0 (en) Method for treating pain
EP0906104A4 (fr) Procede de traitement de la douleur
AU3813397A (en) Apparatus for treating chondromalicia
IL115784A0 (en) Method for forming emulsions
EP1110078A4 (fr) Systeme et procede d'eclairage adaptatif pour appareil de vision artificielle
SG50018A1 (en) Method for developing treatment
ZA959169B (en) Method for treating anxiety
ZA952022B (en) Method for treating 5HT2B receptor related conditions
IL126759A0 (en) Method for treating inflammation
AU1074397A (en) Method for treating anxiety
IL113395A0 (en) Method and apparatus for providing secure communications
IL126064A0 (en) Method for treating pain
EP0868185A4 (fr) Procede de traitement de la depression
IL130531A0 (en) Method for treating glaucoma
AU7726396A (en) Method for treating anxiety
IL124786A0 (en) Method for treating pain
AU7674796A (en) Method for treating anxiety
EP0769904A4 (fr) Methode de traitement de l'anxiete
EP0783304A4 (fr) Methode de traitement de l'anxiete
ZA971899B (en) Method for treating insomnia
GB9517701D0 (en) Method for treating hyperlipidemia
AP9701121A0 (en) Method for prearing streptogramines
GB9404964D0 (en) Method and apparatus for flushing
HU9501515D0 (en) Boundary-stone, method for place out and apparatus for making boundary-stones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960911;SI PAYMENT 960911

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 471/04 A, 7C 07D 209/16 B, 7C 07D 457/04 B, 7C 07D 457/06 B, 7C 07D 241/04 B, 7C 07D 403/12 B, 7C 07D 261/08 B, 7A 61K 31/551 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010911

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011203